Cargando…
Cyclophosphamide mechanism of action in preclinical tecemotide studies
Autores principales: | Hance, Ken, Tighe, Robert, Qi, Jin, Hastings, William, Qin, Guozhong, Marelli, Bo, Wang, Hong, Yu, Huakui, Zhang, Yanping, Xu, Xiaomei, Guzman, Wilson, Wong, Masie, Kradjian, Giorgio, Brunkhorst, Beatrice, Sabzevari, Helen, Lan, Yan, Hofmeister, Robert, Wolf, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990996/ http://dx.doi.org/10.1186/2051-1426-1-S1-P75 |
Ejemplares similares
-
Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy
por: Kao, Chiao-Jung, et al.
Publicado: (2013) -
The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014) -
NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
por: Xu, Chunxiao, et al.
Publicado: (2021) -
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
por: Schimanski, Carl Christoph, et al.
Publicado: (2020) -
Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)